These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38751206)

  • 1. Bellmunt risk score as a survival predictor in patients with metastatic castration-resistant prostate cancer.
    Büttner T; Klümper N; Weiten R; Lossin P; Latz S; Jacobs C; Ritter M; Hauser S; Ellinger J; Krausewitz P
    Prostate; 2024 Sep; 84(12):1119-1127. PubMed ID: 38751206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.
    Azad AA; Eigl BJ; Leibowitz-Amit R; Lester R; Kollmannsberger C; Murray N; Clayton R; Heng DY; Joshua AM; Chi KN
    Eur Urol; 2015 Mar; 67(3):441-7. PubMed ID: 24508071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry.
    Notohardjo JCL; Kuppen MCP; Westgeest HM; van Moorselaar RJA; Mehra N; Coenen JLLM; van Oort IM; de Vos AI; Vervenne WL; van den Bergh ACM; Aben KKH; Somford DM; Bergman AM; Uyl-de Groot CA; Gerritsen WR; van den Eertwegh AJM
    Eur Urol Focus; 2021 Jul; 7(4):788-796. PubMed ID: 32362484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.
    Al-Ezzi EM; Alqaisi HA; Iafolla MAJ; Wang L; Sridhar SS; Sacher AG; Fallah-Rad N; Jiang DM; Watson GA; Catton CN; Warde PR; Hamilton RJ; Fleshner NE; Zlotta AR; Hansen AR
    Cancer Med; 2021 Sep; 10(17):5775-5782. PubMed ID: 34254464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
    Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
    Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
    Whitney CA; Howard LE; Posadas EM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
    Eur Urol Focus; 2017 Oct; 3(4-5):480-486. PubMed ID: 28753787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
    Wang Z; Liu H; Zhu Q; Chen J; Zhao J; Zeng H
    BMC Cancer; 2024 Jul; 24(1):817. PubMed ID: 38978000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel.
    Man YN; Chen YF
    Int Urol Nephrol; 2019 Dec; 51(12):2189-2199. PubMed ID: 31456101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
    Gebrael G; Hage Chehade C; Sayegh N; Tripathi N; Chigarira B; Goel D; Nordblad B; McFarland TR; Narang A; Srivastava A; Tandar C; Dal E; Jo Y; Galarza Fortuna G; Mathew Thomas V; Sahu KK; Li H; Maughan BL; Swami U; Agarwal N
    Prostate; 2024 Jun; 84(9):888-892. PubMed ID: 38561317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
    Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer.
    Uemura K; Miyoshi Y; Kawahara T; Yoneyama S; Hattori Y; Teranishi J; Kondo K; Moriyama M; Takebayashi S; Yokomizo Y; Yao M; Uemura H; Noguchi K
    BMC Cancer; 2016 Feb; 16():109. PubMed ID: 26883015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
    Romero-Laorden N; Lorente D; de Velasco G; Lozano R; Herrera B; Puente J; López PP; Medina A; Almagro E; Gonzalez-Billalabeitia E; Villla-Guzman JC; González-Del-Alba A; Borrega P; Laínez N; Fernández-Freire A; Hernández A; Rodriguez-Vida A; Chirivella I; Fernandez-Parra E; López-Campos F; Isabel Pacheco M; Morales-Barrera R; Fernández O; Villatoro R; Luque R; Hernando S; Castellano DC; Castro E; Olmos D
    Eur Urol Oncol; 2024 Jun; 7(3):447-455. PubMed ID: 37838555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
    Boegemann M; Khaksar S; Bera G; Birtle A; Dopchie C; Dourthe LM; Everaert E; Hatzinger M; Hercher D; Hilgers W; Matus G; Alvarez LG; Antoni L; Lukac M; Pissart G; Robinson P; Elliott T
    BMC Cancer; 2019 Jan; 19(1):60. PubMed ID: 30642291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
    Halabi S; Lin CY; Small EJ; Armstrong AJ; Kaplan EB; Petrylak D; Sternberg CN; Shen L; Oudard S; de Bono J; Sartor O
    J Natl Cancer Inst; 2013 Nov; 105(22):1729-37. PubMed ID: 24136890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer.
    Sonpavde G; Pond GR; Templeton AJ; Kwon ED; De Bono JS
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):67-71. PubMed ID: 27670718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
    Bauckneht M; Rebuzzi SE; Signori A; Frantellizzi V; Murianni V; Lodi Rizzini E; Mascia M; Lavelli V; Donegani MI; Ponzano M; Gaudiano A; Stazza ML; Licari M; Cavallini L; Laghi V; Cindolo L; Maggi M; Sciarra A; Mammucci P; Sambuceti G; Costa RP; Spanu A; Rubini G; Monari F; De Vincentis G; Fornarini G
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1063-1074. PubMed ID: 34486070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
    Chen WS; Aggarwal R; Zhang L; Zhao SG; Thomas GV; Beer TM; Quigley DA; Foye A; Playdle D; Huang J; Lloyd P; Lu E; Sun D; Guan X; Rettig M; Gleave M; Evans CP; Youngren J; True L; Lara P; Kothari V; Xia Z; Chi KN; Reiter RE; Maher CA; Feng FY; Small EJ; Alumkal JJ;
    Eur Urol; 2019 Nov; 76(5):562-571. PubMed ID: 30928160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer.
    Lorente D; Llacer C; Lozano R; de Velasco G; Romero-Laorden N; Rodrigo M; Sánchez-Iglesias Á; di Capua C; Castro E; Ferrer C; Sánchez-Hernández A; Olmos D
    Eur Urol; 2021 Nov; 80(5):641-649. PubMed ID: 34373138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score.
    Oyenuga M; Halabi S; Oyenuga A; McSweeney S; Morgans AK; Ryan CJ; Prizment A
    Prostate; 2023 May; 83(7):688-694. PubMed ID: 36842158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased circulating polymorphonuclear myeloid-derived suppressor cells are associated with prognosis of metastatic castration-resistant prostate cancer.
    Kobayashi T; Nagata M; Hachiya T; Wakita H; Ikehata Y; Takahashi K; China T; Shimizu F; Lu J; Jin Y; Lu Y; Ide H; Horie S
    Front Immunol; 2024; 15():1372771. PubMed ID: 38887300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.